John J. Pink

3.8k total citations
60 papers, 3.2k citations indexed

About

John J. Pink is a scholar working on Molecular Biology, Oncology and Toxicology. According to data from OpenAlex, John J. Pink has authored 60 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Molecular Biology, 25 papers in Oncology and 10 papers in Toxicology. Recurrent topics in John J. Pink's work include Cancer therapeutics and mechanisms (14 papers), Bioactive Compounds and Antitumor Agents (10 papers) and DNA Repair Mechanisms (9 papers). John J. Pink is often cited by papers focused on Cancer therapeutics and mechanisms (14 papers), Bioactive Compounds and Antitumor Agents (10 papers) and DNA Repair Mechanisms (9 papers). John J. Pink collaborates with scholars based in United States, Taiwan and Myanmar. John J. Pink's co-authors include David A. Boothman, Colleen Tagliarino, V. Craig Jordan, Sarah M. Planchon, Jinming Gao, Hua Ai, Xintao Shuai, Marie E. Varnes, Timothy J. Kinsella and Brent D. Weinberg and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Journal of Biological Chemistry.

In The Last Decade

John J. Pink

59 papers receiving 3.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John J. Pink United States 28 1.8k 820 771 666 417 60 3.2k
Roger M. Phillips United Kingdom 38 2.1k 1.1× 1.4k 1.7× 545 0.7× 1.7k 2.6× 185 0.4× 162 4.9k
Аlexander А. Shtil Russia 33 2.3k 1.2× 938 1.1× 307 0.4× 772 1.2× 98 0.2× 255 4.4k
Giovanni Luca Beretta Italy 33 2.0k 1.1× 1.0k 1.2× 339 0.4× 562 0.8× 81 0.2× 127 3.1k
Andrzej Składanowski Poland 27 2.1k 1.1× 1.1k 1.3× 283 0.4× 548 0.8× 93 0.2× 62 2.9k
Mary K. Danks United States 39 3.4k 1.8× 2.0k 2.5× 249 0.3× 503 0.8× 420 1.0× 99 5.0k
Erik A. Bey United States 26 1.9k 1.1× 501 0.6× 1.0k 1.3× 971 1.5× 69 0.2× 35 4.0k
Angelika M. Burger United States 37 2.7k 1.5× 981 1.2× 134 0.2× 491 0.7× 236 0.6× 81 4.1k
Steven A. Akman United States 40 2.5k 1.3× 827 1.0× 169 0.2× 229 0.3× 211 0.5× 108 4.3k
Rosanna Supino Italy 37 3.0k 1.6× 1.7k 2.1× 230 0.3× 593 0.9× 165 0.4× 109 4.9k
Suzanne M. Cutts Australia 29 1.7k 0.9× 663 0.8× 135 0.2× 357 0.5× 140 0.3× 77 2.7k

Countries citing papers authored by John J. Pink

Since Specialization
Citations

This map shows the geographic impact of John J. Pink's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John J. Pink with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John J. Pink more than expected).

Fields of papers citing papers by John J. Pink

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John J. Pink. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John J. Pink. The network helps show where John J. Pink may publish in the future.

Co-authorship network of co-authors of John J. Pink

This figure shows the co-authorship network connecting the top 25 collaborators of John J. Pink. A scholar is included among the top collaborators of John J. Pink based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John J. Pink. John J. Pink is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Schmitz, Kathryn H., Nathan A. Berger, Cynthia Owusu, et al.. (2025). TeleHealth Resistance exercise Intervention to preserve dose intensity and Vitality in Elder Breast Cancer Patients (THRIVE 65). Contemporary Clinical Trials. 158. 108074–108074.
2.
Chang, Ting-Yu, Moeez Rathore, Wei‐Jan Huang, et al.. (2024). Combined HDAC8 and checkpoint kinase inhibition induces tumor-selective synthetic lethality in preclinical models. Journal of Clinical Investigation. 134(23). 4 indexed citations
3.
Qing, Yulan, Ricky Chan, Pingfu Fu, et al.. (2023). Impact of age, antiretroviral therapy, and cancer on epigenetic aging in people living with HIV. Cancer Medicine. 12(9). 11010–11019. 4 indexed citations
4.
Yu, Wesley Y., E. Ricky Chan, John J. Pink, et al.. (2021). Computational Drug Repositioning Identifies Statins as Modifiers of Prognostic Genetic Expression Signatures and Metastatic Behavior in Melanoma. Journal of Investigative Dermatology. 141(7). 1802–1809. 7 indexed citations
5.
Eads, Jennifer R., Smitha Krishnamurthi, Joel Saltzman, et al.. (2020). Phase I clinical trial of temozolomide and methoxyamine (TRC-102), an inhibitor of base excision repair, in patients with advanced solid tumors. Investigational New Drugs. 39(1). 142–151. 10 indexed citations
6.
Yan, Yan, Yulan Qing, John J. Pink, & Stanton L. Gerson. (2017). Loss of Uracil DNA Glycosylase Selectively Resensitizes p53-Mutant and -Deficient Cells to 5-FdU. Molecular Cancer Research. 16(2). 212–221. 21 indexed citations
7.
Ahmad, Shabbir, Sarah Huff, John J. Pink, et al.. (2015). Identification of Non-nucleoside Human Ribonucleotide Reductase Modulators. Journal of Medicinal Chemistry. 58(24). 9498–9509. 14 indexed citations
8.
Dermawan, Josephine Kam Tai, Katerina V. Gurova, John J. Pink, et al.. (2014). Quinacrine Overcomes Resistance to Erlotinib by Inhibiting FACT, NF-κB, and Cell-Cycle Progression in Non–Small Cell Lung Cancer. Molecular Cancer Therapeutics. 13(9). 2203–2214. 55 indexed citations
9.
Bey, Erik A., Kathryn E. Reinicke, Melissa C. Srougi, et al.. (2013). Catalase Abrogates β-Lapachone–Induced PARP1 Hyperactivation–Directed Programmed Necrosis in NQO1-Positive Breast Cancers. Molecular Cancer Therapeutics. 12(10). 2110–2120. 84 indexed citations
10.
Ogba, Ndiya, et al.. (2011). HEXIM1 is a critical determinant of the response to tamoxifen. Oncogene. 30(33). 3563–3569. 18 indexed citations
11.
Kunos, Charles A., Valdir Colussi, John J. Pink, Tomas Radivoyevitch, & Nancy L. Oleinick. (2011). Radiosensitization of Human Cervical Cancer Cells by Inhibiting Ribonucleotide Reductase: Enhanced Radiation Response at Low-Dose Rates. International Journal of Radiation Oncology*Biology*Physics. 80(4). 1198–1204. 19 indexed citations
12.
Zhong, Bo, Xin Yi, Lili Liu, et al.. (2011). From COX-2 inhibitor nimesulide to potent anti-cancer agent: Synthesis, in vitro, in vivo and pharmacokinetic evaluation. European Journal of Medicinal Chemistry. 47(1). 432–444. 53 indexed citations
13.
Kunos, Charles A., Tomas Radivoyevitch, John J. Pink, et al.. (2010). Ribonucleotide Reductase Inhibition Enhances Chemoradiosensitivity of Human Cervical Cancers. Radiation Research. 174(5). 574–581. 47 indexed citations
14.
Yu, Jing, Pingfu Fu, John J. Pink, et al.. (2010). HPV Infection and EGFR Activation/Alteration in HIV-Infected East African Patients with Conjunctival Carcinoma. PLoS ONE. 5(5). e10477–e10477. 25 indexed citations
15.
Bey, Erik A., Shelly M. Wuerzberger‐Davis, John J. Pink, et al.. (2006). Mornings with art, lessons learned: Feedback regulation, restriction threshold biology, and redundancy govern molecular stress responses. Journal of Cellular Physiology. 209(3). 604–610. 22 indexed citations
16.
Ai, Hua, John J. Pink, Xintao Shuai, David A. Boothman, & Jinming Gao. (2005). Interactions between self‐assembled polyelectrolyte shells and tumor cells. Journal of Biomedical Materials Research Part A. 73A(3). 303–312. 58 indexed citations
17.
Nasongkla, Norased, Xintao Shuai, Hua Ai, et al.. (2004). cRGD‐Functionalized Polymer Micelles for Targeted Doxorubicin Delivery. Angewandte Chemie International Edition. 43(46). 6323–6327. 359 indexed citations
18.
Tagliarino, Colleen, et al.. (2003). μ-Calpain Activation in β-Lapachone-Mediated Apoptosis. Cancer Biology & Therapy. 2(2). 141–152. 81 indexed citations
19.
Tagliarino, Colleen, John J. Pink, George Dubyak, Anna‐Liisa Nieminen, & David A. Boothman. (2001). Calcium Is a Key Signaling Molecule in β-Lapachone-mediated Cell Death. Journal of Biological Chemistry. 276(22). 19150–19159. 134 indexed citations
20.
Pink, John J., Sarah M. Planchon, Colleen Tagliarino, et al.. (2000). NAD(P)H:Quinone Oxidoreductase Activity Is the Principal Determinant of β-Lapachone Cytotoxicity. Journal of Biological Chemistry. 275(8). 5416–5424. 327 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Roger M. Phillips Breakdown of academic impact, for papers by Аlexander А. Shtil Breakdown of academic impact, for papers by Giovanni Luca Beretta Breakdown of academic impact, for papers by Andrzej Składanowski Breakdown of academic impact, for papers by Mary K. Danks Breakdown of academic impact, for papers by Erik A. Bey Breakdown of academic impact, for papers by Angelika M. Burger Breakdown of academic impact, for papers by Steven A. Akman Breakdown of academic impact, for papers by Rosanna Supino Breakdown of academic impact, for papers by Suzanne M. Cutts
Rankless by CCL
2026